In:
CNS Neuroscience & Therapeutics, Wiley, Vol. 30, No. 3 ( 2024-03)
Kurzfassung:
To explore the pharmacological treatment of vascular depression (VaDep) and whether the blood levels of neurotransmitters can reflect the VaDep severity. Methods VaDep patients with somatic symptoms were enrolled and randomly received venlafaxine + tandospirone (Combined Group) or venlafaxine (Monotherapy Group). The treatment efficacy was assessed by Hamilton Depression Scale (HAMD), Hamilton Anxiety Scale (HAMA), and Patient Health Questionnaire‐15 (PHQ‐15). The levels of blood monoamine neurotransmitters were measured by enzyme‐linked immunosorbent assay. Results Both groups reported a progressive decrease in HAMD, HAMA, and PHQ‐15 scores to below the baseline after the respective treatment. Compared with the Monotherapy Group, the Combined Group reported a significant decrease in HAMD score at week 2 and markedly lower HAMA and PHQ‐15 scores at weeks 1, 2, 4, and 8. Both groups showed a decrease in the levels of blood monoamine neurotransmitters at weeks 4 and 8 when compared with the baseline. A strong positive association was evident between the plasma 5‐HT levels and the HAMD score. Conclusion The combined therapy rapidly acts on VaDep comorbid with anxiety and somatic symptoms and significantly alleviates the anxiety and somatic symptoms. The plasma levels of 5‐HT may serve as potential objective candidates in evaluating VaDep severity and the efficacy of the undertaken treatment regimen.
Materialart:
Online-Ressource
ISSN:
1755-5930
,
1755-5949
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2024
ZDB Id:
2423467-9